Conjugates of biologically stable polyfunctional molecules and polynucleotides for treating systemic lupus erythematosus
US5276013A · kind A · utility
25Cited by
5References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 15, 1992 |
| Grant date | Jan 4, 1994 |
| Priority date | — |
| Expiry date | Jul 15, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6093
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Chemically defined conjugates of biologically stable valency platform molecules, such as copolymers of D-glutamic acid and D-lysine or polyethylene glycol, and polynucleotide duplexes of at least 20 base pairs that have significant binding activity for human lupus anti-dsDNA autoantibodies. The duplexes are preferably homogeneous in length structure and are bound to the valency platform molecule via reaction between a functional group located at or proximate a terminus of each duplex and functional groups on the valency platform molecule. These conjugates are tolerogens for human systemic lupus erythematosus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.